I am a board-certified medical oncologist who specializes in caring for people with gastrointestinal cancers. These include colorectal cancer, hepatobiliary cancer, esophageal cancer, stomach cancer, and pancreatic cancer. I see patients at Memorial Sloan Kettering Commack. I feel privileged to provide state-of-the-art care to our patients close to home on Long Island.
As a member of MSK’s Gastrointestinal Oncology Service, I am part of a team of experts from different areas. My colleagues include medical oncologists, surgical oncologists, radiation oncologists, radiologists, psychiatrists, oncology nurses, social workers, and dieticians.
We provide our patients with the highest-quality care. We also offer access to many cancer clinical trials at MSK Commack and help patients enroll in studies based at MSK in Manhattan.
My research has focused on developing new therapies for gastrointestinal cancers. I am currently a lead and co-lead author for several early-phase trials for pancreatic cancer, gastric cancer, and esophageal cancer. I also have written several book chapters on cancer care.
- Clinical Expertise: Gastrointestinal Malignancies
- Languages Spoken: English; Mandarin
- Education: MD, Tianjin Medical University; PhD, Albert Einstein College of Medicine
- Residencies: Jacobi Medical Center
- Fellowships: Yale Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology and Hematology
Li J, Kluger H, Lesley D, et al. Phase I Study of Safety and Tolerability of Sunitinib in Combination with Sirolimus in Patients with Refractory Solid Malignancies and Determination of VEGF (VEGF A) and soluble VEGF-R2 (sVEGFR2) in plasma. Cancer Chemotherapy and Pharmacology. 2016, Apr 21 [Epub ahead of print]
Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114(7):809-12.
Li J, Yao X, Kortmansky JS, et al. Phase II study of modified FOLFOX6 with bevacizumab in metastatic gastroesophageal adenocarcinoma. AJCO. 2014 Aug 20 (Epub ahead of print).
Saif MW, Li J, Lamb L, et al. First-in-human Phase II Trial of the Botanical Formulation PHY906 with Capecitabine as Second-line Therapy in Patients with Advanced Pancreatic Cancer. Cancer Chemother Pharmacol. 2014;73(2):373-380
Zhang X, Li J. Era of universal testing of microsatellite instability in colorectal cancer. World J Gastrointest Oncol. 2013;5(2):12-9.
Li J, Merl MY, Lee MX, et al. Safety and efficacy of single day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert Opinion on Drug Safety. 2010;9(2):207-13.
Li J, Saif MW. Current use and potential role of bevacizumab in gastrointestinal cancers. Biologics: Target & Therapy 2009;3:429-441.
Li J, Podoltsev N, Saif MW. Management of advanced pancreatic cancer. Expert Review of Clinical Pharmacology 2009:2(5):527-541.
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more